Logo image of ASLN

ASLAN Pharmaceuticals Ltd (ASLN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ASLN - US04522R2004 - ADR

0.6 USD
-0.1 (-14.27%)
Last: 7/18/2024, 8:00:00 PM
0.56 USD
-0.04 (-6.67%)
After Hours: 7/18/2024, 8:00:00 PM
Fundamental Rating

1

Taking everything into account, ASLN scores 1 out of 10 in our fundamental rating. ASLN was compared to 533 industry peers in the Biotechnology industry. ASLN may be in some trouble as it scores bad on both profitability and health. ASLN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ASLN had negative earnings in the past year.
In the past 5 years ASLN always reported negative net income.
ASLN had a negative operating cash flow in each of the past 5 years.
ASLN Yearly Net Income VS EBIT VS OCF VS FCFASLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

ASLN has a worse Return On Assets (-93.07%) than 75.96% of its industry peers.
Looking at the Return On Equity, with a value of -806.53%, ASLN is doing worse than 82.40% of the companies in the same industry.
Industry RankSector Rank
ROA -93.07%
ROE -806.53%
ROIC N/A
ROA(3y)-72.62%
ROA(5y)-99.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASLN Yearly ROA, ROE, ROICASLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 1K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ASLN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASLN Yearly Profit, Operating, Gross MarginsASLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

There is no outstanding debt for ASLN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ASLN Yearly Shares OutstandingASLN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 100K 200K 300K 400K
ASLN Yearly Total Debt VS Total AssetsASLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

ASLN has an Altman-Z score of -9.77. This is a bad value and indicates that ASLN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ASLN (-9.77) is worse than 77.35% of its industry peers.
A Debt/Equity ratio of 3.84 is on the high side and indicates that ASLN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.84, ASLN is doing worse than 82.93% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.84
Debt/FCF N/A
Altman-Z -9.77
ROIC/WACCN/A
WACCN/A
ASLN Yearly LT Debt VS Equity VS FCFASLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 2.26 indicates that ASLN has no problem at all paying its short term obligations.
ASLN has a worse Current ratio (2.26) than 74.39% of its industry peers.
ASLN has a Quick Ratio of 2.26. This indicates that ASLN is financially healthy and has no problem in meeting its short term obligations.
ASLN has a worse Quick ratio (2.26) than 73.17% of its industry peers.
Industry RankSector Rank
Current Ratio 2.26
Quick Ratio 2.26
ASLN Yearly Current Assets VS Current LiabilitesASLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ASLN have decreased strongly by -173.28% in the last year.
EPS 1Y (TTM)-173.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ASLN will show a very strong growth in Earnings Per Share. The EPS will grow by 30.68% on average per year.
ASLN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.90% yearly.
EPS Next Y58.45%
EPS Next 2Y30.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y36.9%

3.3 Evolution

ASLN Yearly Revenue VS EstimatesASLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2019 2023 2028 2029 2030 200M 400M 600M 800M 1B
ASLN Yearly EPS VS EstimatesASLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ASLN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASLN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASLN Price Earnings VS Forward Price EarningsASLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASLN Per share dataASLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as ASLN's earnings are expected to grow with 30.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.68%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ASLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASLAN Pharmaceuticals Ltd

NASDAQ:ASLN (7/18/2024, 8:00:00 PM)

After market: 0.56 -0.04 (-6.67%)

0.6

-0.1 (-14.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-31 2024-05-31/amc
Earnings (Next)08-09 2024-08-09/bmo
Inst Owners0.84%
Inst Owner Change-71.29%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.70M
Revenue(TTM)N/A
Net Income(TTM)-51.38M
Analysts82.5
Price Target77.52 (12820%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.65%
Min EPS beat(2)68.77%
Max EPS beat(2)86.52%
EPS beat(4)3
Avg EPS beat(4)39.54%
Min EPS beat(4)-14.56%
Max EPS beat(4)86.52%
EPS beat(8)5
Avg EPS beat(8)20.2%
EPS beat(12)6
Avg EPS beat(12)11.09%
EPS beat(16)7
Avg EPS beat(16)-18.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)700%
PT rev (3m)700%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 0.27
EV/EBITDA N/A
EPS(TTM)-11.15
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS2.25
TBVpS2.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -93.07%
ROE -806.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-72.62%
ROA(5y)-99.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 3.84
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.26
Quick Ratio 2.26
Altman-Z -9.77
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)8.6%
Cap/Depr(5y)11.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-173.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.68%
EPS Next Y58.45%
EPS Next 2Y30.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y36.9%
EBIT growth 1Y-41.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.96%
OCF growth 3YN/A
OCF growth 5YN/A

ASLAN Pharmaceuticals Ltd / ASLN FAQ

What is the ChartMill fundamental rating of ASLAN Pharmaceuticals Ltd (ASLN) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ASLN.


Can you provide the valuation status for ASLAN Pharmaceuticals Ltd?

ChartMill assigns a valuation rating of 1 / 10 to ASLAN Pharmaceuticals Ltd (ASLN). This can be considered as Overvalued.


How profitable is ASLAN Pharmaceuticals Ltd (ASLN) stock?

ASLAN Pharmaceuticals Ltd (ASLN) has a profitability rating of 0 / 10.